Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study

Biliary tract cancer (BTC) is constituted by a heterogeneous group of malignant tumors that may develop in the biliary tract, and it is the second most common liver cancer. Human ribonucleotide reductase M1 (hRRM1) has already been proven to be a potential BTC target. In the current study, a de novo...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Md Ataul, Barshetty, Mayuri Makarand, Srinivasan, Sridhar, Dudekula, Dawood Babu, Rallabandi, V. P. Subramanyam, Mohammed, Sameer, Natarajan, Sathishkumar, Park, Junhyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496582/
https://www.ncbi.nlm.nih.gov/pubmed/36139117
http://dx.doi.org/10.3390/biom12091279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496582/
https://www.ncbi.nlm.nih.gov/pubmed/36139117
http://dx.doi.org/10.3390/biom12091279

Ejemplares similares